New hope for Tough-to-Treat breast cancer: experimental drug challenges standard chemo

This study is testing whether a new drug called SYS6010 works better than standard chemotherapy for people with a specific type of advanced breast cancer that has returned or spread. It will involve about 400 adults whose cancer is HER2-negative but EGFR-positive and has worsened after one or two rounds of prior chemotherapy. Participants will be randomly assigned to receive either the new SYS6010 treatment or one of several standard chemotherapy options chosen by their doctor.